Clinical

Panelists discuss how diuretics serve as necessary “bailout therapy” for volume management in heart failure but should not substitute for guideline-directed medical therapy, with emerging evidence supporting more nuanced approaches to diuresis, including urinalysis monitoring and novel formulations like intranasal furosemide, while noting that effective heart failure therapies actually reduce diuretic requirements.

Panelists discuss how β-blockers remain foundational therapy for heart failure with reduced ejection fraction (using evidence-based agents like carvedilol, metoprolol succinate, or bisoprolol) with proven mortality benefits, while their role in heart failure with preserved ejection fraction is more questionable and potentially overused unless atrial fibrillation is present.

Guidelines that encouraged the exposure of peanuts in children were found to significantly reduce food allergies.

Results from the ASPEN trial also show that brensocatib displayed several benefits when used in patients with bronchiectasis, including a reduction in symptom burden.

Papillary muscle scarring (papSCAR) was found to be associated with increased risk of cardiac death in patients with dilated cardiomyopathy

Arielle Kauvar, MD, says pre- and post-treatment care helps prevent hyperpigmentation and complications from laser procedures for all skin types, including skin of color.

Women who received the mRNA COVID-19 vaccine in their first trimester did not have an increased risk of their child having a major congenital malformation.

Persistent racial, ethnic, and socioeconomic disparities affect the incidence and mortality of major female-specific cancers in the US.

Patients beginning their cancer journeys should advocate for themselves and use support groups to help navigate survivorship challenges.

Long COVID is most common among adults with chronic conditions, lower physical activity, and incomplete vaccination, and who live in certain US regions.

An expert discusses how rilzabrutinib uniquely improves quality-of-life metrics, including fatigue and women’s health domains, which previous immune thrombocytopenia (ITP) therapies failed to address despite raising platelet counts. An expert discusses how rilzabrutinib’s oral administration and broad tolerability make it a practical treatment option while emphasizing the need for long-term efficacy and safety data to strengthen clinical confidence.

An expert discusses how rilzabrutinib uniquely improves quality-of-life metrics, including fatigue and women’s health domains, which previous immune thrombocytopenia (ITP) therapies failed to address despite raising platelet counts.

Individuals who had preoperative percutaneous transthoracic needle biopsy (PTNB) had an increased risk of local-regional recurrence in non–small cell lung cancer (NSCLC).

The LINKER-SMM1 trial shows promising results for linvoseltamab in treating high-risk smoldering multiple myeloma with a favorable safety profile, notes Paula Rodríguez-Otero, MD, PhD.

Experts discussed safe and effective management strategies for patients with hidradenitis suppurativa at the 2025 Skin of Color Update.

Panelists discuss how the SUNLIGHT trial and real-world evidence support FTD/TPI with or without bevacizumab as an effective third-line option in metastatic colorectal cancer.

Panelists discuss how available third-line therapies, such as FTD/TPI, regorafenib, and others, are chosen based on survival data, safety, and patient quality of life.

Arthritis care remains fragmented and costly, with access disparities prompting calls for preventive strategies, community resources, and systemic improvements.

Panelists discuss how current NCCN guidelines emphasize the importance of treating AML at experienced centers with proper infrastructure, while treatment decisions are based on intensive vs nonintensive therapy eligibility and specific genetic mutations like FLT3, IDH1, and TP53.

Panelists discuss how social determinants of health significantly impact AML care, particularly regarding transportation access, health literacy, and the intensive nature of treatment requiring frequent clinic visits for blood work and transfusions, which disproportionately affects patients living far from treatment centers.

The founder and President of Phesi addresses the need for streamlining clinical trial data as GLP-1 RA therapies are being used to treat multiple diseases.

Many cancer survivors face ongoing physical and mental health challenges, which peer support and online resources can help address, says Brian Koffman, MDCM, DCFP, FCFP, DABFP, MSEd.

Panelists discuss how the CONVOKE clinical trial was designed as a 16-week study focusing specifically on patients with negative symptoms, incorporating patient input in app development and showing improvements in negative symptoms, depression, and cognitive function even in chronically ill patients.

Panelists discuss how prescription digital therapeutics are currently used in clinical practice, noting that while none are yet approved for schizophrenia, CT-155 shows promise in phase 3 trials, and existing PDTs like Rejoyn for depression demonstrate the potential for technology-based interventions.

Panelists discuss how guideline-directed medical therapy has evolved to include 4-pillar treatment for heart failure with reduced ejection fraction (angiotensin-converting enzyme inhibitors/angiotensin receptor‐neprilysin inhibitors, β-blockers, mineralocorticoid receptor antagonists, SGLT2 inhibitors) that can reduce mortality by up to 60% and extend life by 6 years, though significant implementation gaps remain, with only about one-third of eligible patients receiving appropriate therapy, necessitating rapid initiation of all 4 drug classes within weeks rather than sequential titration.